Clinical Trial Update: Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating whether adding entecavir to ongoing peginterferon alfa-2a improves efficacy in HBeAg-negative, HBV DNA-positive chronic hepatitis B p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Baraclude (entecavir)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Beijing Ditan Hospital | Conditions: Chronic Hepatitis B | Phase 4 | Status: UNKNOWN